Ontwikkelingen in de zorg voor patiënten met pancreascarcinoom

Simone Augustinus; Olivier R Busch; Bert A Bonsing; Marco J Bruno; Jan Willem B de Groot; Bas Groot Koerkamp; Martijn P W Intven; Frank Köhler; Quintus Molenaar; Johanna W Wilmink; Marc G Besselink

Ontwikkelingen in de zorg voor patiënten met pancreascarcinoom

Translated title of the contribution: Nationwide multidisciplinary developments in pancreatic cancer care in the Netherlands

Simone Augustinus, Olivier R Busch, Bert A Bonsing, Marco J Bruno, Jan Willem B de Groot, Bas Groot Koerkamp, Martijn P W Intven, Frank Köhler, Quintus Molenaar, Johanna W Wilmink, Marc G Besselink

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In the past years several developments have occurred in the care for patients with pancreatic cancer in the Netherlands. New palliative chemotherapy strategies using FOLFRINOX or gemcitabine/nab-paclitaxel were introduced for patients with advanced disease. Due to centralization of pancreatic surgery, introduction of neoadjuvant therapy, and the implementation of standardized postoperative care more patients became enable for resection, postoperative mortality decreased, and survival improved. Within the randomized PREOPANC trial of the Dutch Pancreatic Cancer Group (DPCG), neoadjuvant therapy using chemoradiation for (borderline) resectable pancreatic cancer improved five-year survival from 7% to 21%. Furthermore, due to nationwide training programs, the use of minimally invasive surgery has increased. Regardless of these developments, the survival of patients with pancreatic cancer is still low and 61% of Dutch patients with pancreatic cancer patients do not receive any tumor targeted therapy. The DPCG is active to improve quality of care through auditing, research, guideline development, and education.

Translated title of the contribution	Nationwide multidisciplinary developments in pancreatic cancer care in the Netherlands
Original language	Dutch
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	167
Publication status	Published - 15 Nov 2023

Keywords

Humans
Gemcitabine
Deoxycytidine/therapeutic use
Netherlands
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Pancreatic Neoplasms/pathology

Access to Document

https://www.ntvg.nl/artikelen/ontwikkelingen-de-zorg-voor-patienten-met-pancreascarcinoom

Cite this

Augustinus, S., Busch, O. R., Bonsing, B. A., Bruno, M. J., de Groot, J. W. B., Groot Koerkamp, B., Intven, M. P. W., Köhler, F., Molenaar, Q., Wilmink, J. W., & Besselink, M. G. (2023). Ontwikkelingen in de zorg voor patiënten met pancreascarcinoom. Nederlands Tijdschrift voor Geneeskunde, 167. https://www.ntvg.nl/artikelen/ontwikkelingen-de-zorg-voor-patienten-met-pancreascarcinoom

@article{389c64d4469746be9a9143e3e791ca7c,

title = "Ontwikkelingen in de zorg voor pati{\"e}nten met pancreascarcinoom",

abstract = "In the past years several developments have occurred in the care for patients with pancreatic cancer in the Netherlands. New palliative chemotherapy strategies using FOLFRINOX or gemcitabine/nab-paclitaxel were introduced for patients with advanced disease. Due to centralization of pancreatic surgery, introduction of neoadjuvant therapy, and the implementation of standardized postoperative care more patients became enable for resection, postoperative mortality decreased, and survival improved. Within the randomized PREOPANC trial of the Dutch Pancreatic Cancer Group (DPCG), neoadjuvant therapy using chemoradiation for (borderline) resectable pancreatic cancer improved five-year survival from 7% to 21%. Furthermore, due to nationwide training programs, the use of minimally invasive surgery has increased. Regardless of these developments, the survival of patients with pancreatic cancer is still low and 61% of Dutch patients with pancreatic cancer patients do not receive any tumor targeted therapy. The DPCG is active to improve quality of care through auditing, research, guideline development, and education.",

keywords = "Humans, Gemcitabine, Deoxycytidine/therapeutic use, Netherlands, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Pancreatic Neoplasms/pathology",

author = "Simone Augustinus and Busch, {Olivier R} and Bonsing, {Bert A} and Bruno, {Marco J} and {de Groot}, {Jan Willem B} and {Groot Koerkamp}, Bas and Intven, {Martijn P W} and Frank K{\"o}hler and Quintus Molenaar and Wilmink, {Johanna W} and Besselink, {Marc G}",

year = "2023",

month = nov,

day = "15",

language = "Dutch",

volume = "167",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Bohn Stafleu van Loghum",

}

TY - JOUR

T1 - Ontwikkelingen in de zorg voor patiënten met pancreascarcinoom

AU - Augustinus, Simone

AU - Busch, Olivier R

AU - Bonsing, Bert A

AU - Bruno, Marco J

AU - de Groot, Jan Willem B

AU - Groot Koerkamp, Bas

AU - Intven, Martijn P W

AU - Köhler, Frank

AU - Molenaar, Quintus

AU - Wilmink, Johanna W

AU - Besselink, Marc G

PY - 2023/11/15

Y1 - 2023/11/15

N2 - In the past years several developments have occurred in the care for patients with pancreatic cancer in the Netherlands. New palliative chemotherapy strategies using FOLFRINOX or gemcitabine/nab-paclitaxel were introduced for patients with advanced disease. Due to centralization of pancreatic surgery, introduction of neoadjuvant therapy, and the implementation of standardized postoperative care more patients became enable for resection, postoperative mortality decreased, and survival improved. Within the randomized PREOPANC trial of the Dutch Pancreatic Cancer Group (DPCG), neoadjuvant therapy using chemoradiation for (borderline) resectable pancreatic cancer improved five-year survival from 7% to 21%. Furthermore, due to nationwide training programs, the use of minimally invasive surgery has increased. Regardless of these developments, the survival of patients with pancreatic cancer is still low and 61% of Dutch patients with pancreatic cancer patients do not receive any tumor targeted therapy. The DPCG is active to improve quality of care through auditing, research, guideline development, and education.

AB - In the past years several developments have occurred in the care for patients with pancreatic cancer in the Netherlands. New palliative chemotherapy strategies using FOLFRINOX or gemcitabine/nab-paclitaxel were introduced for patients with advanced disease. Due to centralization of pancreatic surgery, introduction of neoadjuvant therapy, and the implementation of standardized postoperative care more patients became enable for resection, postoperative mortality decreased, and survival improved. Within the randomized PREOPANC trial of the Dutch Pancreatic Cancer Group (DPCG), neoadjuvant therapy using chemoradiation for (borderline) resectable pancreatic cancer improved five-year survival from 7% to 21%. Furthermore, due to nationwide training programs, the use of minimally invasive surgery has increased. Regardless of these developments, the survival of patients with pancreatic cancer is still low and 61% of Dutch patients with pancreatic cancer patients do not receive any tumor targeted therapy. The DPCG is active to improve quality of care through auditing, research, guideline development, and education.

KW - Humans

KW - Gemcitabine

KW - Deoxycytidine/therapeutic use

KW - Netherlands

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Pancreatic Neoplasms/pathology

M3 - Article

C2 - 37994711

SN - 0028-2162

VL - 167

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

ER -

Ontwikkelingen in de zorg voor patiënten met pancreascarcinoom

Abstract

Keywords

Access to Document

Fingerprint

Cite this